

Prevalence, Clinical Signs, Diagnosis and Treatment of Post-Pandemic SARS-CoV-2 Infection in Cats in 2023. Co-Infection with FHV, FCV, *Mycoplasma* spp. and *Chlamydia felis*—A Single-Center Study in Bulgaria

[Ivo Sirakov, PhD](#)*, [Milena Krastanova](#), [Nikolina Rusenova](#), [Stoyan Shishkova](#), [Anton Rusenov](#), [Bilyana Sirakova](#), [Kalina Mihova](#), [Kalina Shishkova](#)

Posted Date: 17 March 2026

doi: 10.20944/preprints202603.1376.v1

Keywords: SARS-CoV-2; post-pandemic; animals; co-infection; upper respiratory tract; pathogens



Preprints.org is a free multidisciplinary platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This open access article is published under a [Creative Commons CC BY 4.0 license](#), which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.

Disclaimer/Publisher's Note: The statements, opinions, and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions, or products referred to in the content.

Article

Prevalence, Clinical Signs, Diagnosis and Treatment of Post-Pandemic SARS-CoV-2 Infection in Cats in 2023. Co-Infection with FHV, FCV, *Mycoplasma* spp. and *Chlamydia felis* – A Single-Center Study in Bulgaria

Ivo Sirakov ^{1,*}, Milena Krastanova ², Nikolina Rusenova ³, Stoyan Shishkov ⁴, Anton Rusenov ⁵, Bilyana Sirakova ⁴, Kalina Mihova ⁶ and Kalina Shishkova ⁴

- ¹ Department of Medical Microbiology “Corr. Mem. Prof. Ivan Mitov, MD, DMSc”, Faculty of Medicine, Medical University of Sofia, 2 Zdrave Str., 1431 Sofia, Bulgaria
 - ² Department of Anatomy, Physiology and Animal Sciences, Faculty of Veterinary Medicine, University of Forestry, Sofia, Bulgaria
 - ³ Department of Veterinary Microbiology, Infectious and Parasitic Diseases, Faculty of Veterinary Medicine, Trakia University, 6000 Stara Zagora, Bulgaria
 - ⁴ Laboratory of Virology, Faculty of Biology, University of Sofia “St. Kl. Ohridski”, 8 Dragan Tzankov Blvd., 1164 Sofia, Bulgaria
 - ⁵ Department of Internal Diseases, Faculty of Veterinary Medicine, Trakia University, 6000 Stara Zagora, Bulgaria
 - ⁶ Molecular Medicine Center, Department of Medical Chemistry and Biochemistry, Medical Faculty, Medical University, 1431 Sofia, Bulgaria
- * Correspondence: insirakov@gmail.com; +359 898522822

Simple Summary

The SARS-CoV-2 pandemic, COVID-19, has primarily affected humans, but also domestic cats. Cats can transmit the virus through secretions from the mouth, nose, throat and feces without clinical symptoms and signs of disease. The study included 102 cats in Bulgaria in 2023 that showed signs of disease. The frequency of SARS-CoV-2 infection and its impact on animals was monitored. The tests we used included virus detection, virus cultivation in cell lines, antibody testing and screening for other pathogens such as *Feline herpesvirus*, *Feline calicivirus*, *Chlamydia felis* and *Mycoplasma* spp. In 21 cats, the SARS-CoV-2 test was positive and only four of the cats were free of infection with other pathogens. Most of the cats studied are domestic, with currently healthy owners, suggesting probable transmission of the infection from people who were asymptomatic or had recovered. Clinical signs in the cats were mild - discharge from the eyes, sneezing and lethargy. The animals recovered after supportive treatment to stimulate the immune system. SARS-CoV-2 was isolated from the four cats, which were not carriers of the other pathogens studied. Successful cultivation shows that the virus was infectious and it can be concluded that domestic cats can become infected and spread SARS-CoV-2, even with mild symptoms. Understanding the circulation of the virus among cats helps to prevent animal and human health.

Abstract

SARS-CoV-2 is a zoonotic virus with a proven ability to infect various animal species, including domestic cats. In the post-pandemic period of COVID 19, there are still limited data on the clinical course, shedding of infectious virus and diagnostic features in cats. The aim of this study was to investigate the spread of SARS-CoV-2 in cats in 2023, the clinical manifestations of the infection, the diagnostic algorithm including molecular detection of viral components, differential diagnosis of co-infection with FHV, FCV, *Mycoplasma* spp. and *Chlamydia felis*, serology and isolation of infectious

SARS-CoV-2. The immunomodulatory therapy in animals with a standalone SARS-CoV-2 infection was applied. The study included oropharyngeal, conjunctival and nasal swab samples from 102 domestic cats with clinical signs. Of them, 20.6% (21/102) were positive for SARS-CoV-2, with 16.67% (17/102) of the cats showing various variants of co-infection with FHV, FCV, *Mycoplasma spp.* and *Chlamydia felis*. Four of the cats had a standalone SARS-CoV-2 with mild clinical manifestations that included serous discharges from the eyes, without change in the general condition. The virus was isolated from these samples. These four cats and their owners were positive for antibodies to the virus, and the owners were PCR-negative. The treatment of SARS-CoV-2 infection included the preparations Viusid, RX immunosupport, Vetomun and Lisymun. This is one of the first post-pandemic study covering FHV, FCV, *Mycoplasma spp.* and *Chlamydia felis* in domestic cats with SARS-CoV-2 infection and further expands on the essential main idea including the specified pathogens of interest.

Keywords: SARS-CoV-2; post-pandemic; animals; co-infection; upper respiratory tract; pathogens

1. Introduction

SARS-CoV-2 caused the pandemic in 2019 and, in addition to humans, it causes active infection in various animal species such as ferrets [1], minks, dogs and cats [2,3]. Among domestic animals, cats are more susceptible [2,4]. They shed the virus from the oropharynx and feces [5], which can be detected by Real Time PCR [5–9] and conventional PCR [6,10]. Isolation and cultivation of the virus in permissive cell cultures, such as VERO E6, can demonstrate its infectivity [11,12]. However, some SARS-CoV-2 PCR-positive samples from cats result in unsuccessful viral isolation [13]. Other approaches for detection of infection in cats include serological assays [8,14–18]. They are suitable for retrospective studies to provide additional information on the viral spread during a period of interest. Infection can be asymptomatic [19] or the clinical picture may include mild to moderate upper respiratory tract (URT) symptoms such as sneezing and coughing [13,20], and gastrointestinal symptoms [21]. In some cases, there can be complications, such as hypertrophic cardiomyopathy [22], myocarditis, pneumonia [23] and bronchial pneumonia [19].

Studies have shown varying data on the number of SARS-CoV-2 seropositive cats during the pandemic. Depending on whether the cats are of unknown status or live with SARS-CoV-2-positive owners, reports range from 0 to 22.47% [15–17] to 43% [24] – 47.5% [8], respectively. In stray cats, these values can range from 0.8% [25] to 83% [18].

Detected cases of SARS-CoV-2 infection in domestic cats using molecular assays vary from 0.25–0.38% [15,26] to 11.25% [8]. Other studies have used antigen tests to detect SARS-CoV-2, reporting 23.60% positive cases in stray cats [27].

Domestic cats that have no outdoor access acquire the infection from their owners [8,28]. Data on the number of infected cats with outdoor access depends on the degree of compliance with anti-epidemic measures in the respective countries and regions, as the movement of people and their cats contributes to the spread of the virus in the environment [18,29].

Reports have detected active SARS-CoV-2 infection in cats [8,10,26,27] and have demonstrated the possibility for virus circulation among cats and through environmental routes [14,18]. Hence, there are recommendations for the inclusion of SARS-CoV-2 in the diagnostic panel along with *Feline herpesvirus* (FHV), *Feline calicivirus* (FCV), *Mycoplasma spp.* and *Chlamydia felis* [10,30].

There is a growing body of data on SARS-CoV-2 infection in cats. However, most studies have focused on serological prevalence or molecular detection of viral RNA, with less detailed attention to their correlation with the clinical course of infection under natural conditions. There are still limited data on indoor cats with clinical manifestations and probable infection due to contact with asymptomatic or oligosymptomatic owners, especially in the context of complex diagnostic evaluation.

The aim of this study was to investigate the prevalence of post-pandemic SARS-CoV-2 in cats in 2023 and the clinical signs of infection. The diagnostic algorithm included molecular detection, viral isolation in cell culture, serological testing and co-infections with FHV, FCV, *Mycoplasma spp.* and *Chlamydia felis*. Additionally, we evaluated the effect of immunomodulatory therapy in animals infected only with SARS-CoV-2.

2. Materials and Methods

Inclusion Criteria and Sampling

In line with our previous recommendation [10], the Bayvet Veterinary Clinic in Sofia, Bulgaria, included SARS-CoV-2 in the diagnostic panel for infections of the upper respiratory tract and eyes in cats caused by FHV, FCV, *Mycoplasma spp.* and *Chl. felis*. Hence, the inclusion criteria were presence of symptoms such as nasal discharge, conjunctivitis, redness in the oral cavity (gingivitis, stomatitis, pharyngitis and other pathologies), gastrointestinal (GI) disorders (diarrhea) of unknown etiology, as well as the absence of indications that the diet was the cause of the GI disorder.

To obtain samples from the head area (oropharyngeal, conjunctival and nasal swab samples), we used nasopharyngeal polypropylene flocked swabs, CE (Llins Service & Consulting GmbH, Heidelberg, Germany). The swabs were placed in 1.5 or 2.0 mL tubes with 450 µL of saline solution. Swab samples were obtained according to clinical manifestations and placed in a common tube. From this tube, material for nucleic acid extraction was taken.

Storage and transport of fecal samples or swab samples was done in 2.0 mL tubes containing 0.5 mL of physiological saline.

To obtain the virus in cell culture, the samples from cats must be negative for other agents that cause similar symptoms, namely FHV, FCV, mycoplasma and chlamydia (to prevent contamination of the cell culture).

The study included 102 cats from January 5 to December 17, 2023. The owners provided the medical history.

The cats that met the eligibility criteria for virus isolation underwent a physical examination—measurement of body temperature, pulse and respiration. Blood samples were taken for a complete blood count (CBC) and swab samples were taken for PCR analysis.

The owners whose cats met the criteria also had nasal and oropharyngeal swab samples taken for PCR detection of SARS-CoV-2.

All owners completed informed consent forms for the study.

The owners whose cats tested positive for SARS-CoV-2 were surveyed on:

1. How the cats were kept: indoors only, indoors with outdoor access or outdoors only;
2. Whether the cat had been in contact with other cats in the last 7-10 days.
3. Whether any family member had COVID-19 symptoms at the time, or when a family member had last been ill.

The owners filled out informed consent forms for the study, but did not give permission for subsequent blood samples to be taken from their cats (20 days later) for testing for antibodies against SARS-CoV-2, as the cats were aggressive, and the owners wished to avoid further stress to their pets.

Detection of Antibodies Against SARS-CoV-2

Blood samples for detection of antibodies against SARS-CoV-2 were collected from the ring finger of the owners whose cats met the criteria for virus isolation. Blood samples were collected using BD Microtainer® contact-activated lancets (Becton Dickinson Holdings Pte Ltd.). Immunochromatographic lateral flow assays detected anti-SARS-CoV-2 IgG and IgM separately; Artron Rapid COVID-19 Antibody Test ^{CE} (Artron, Canada) according to the manufacturer's instructions was used.

Serum was separated from the blood samples obtained from the cats for CBC and was tested for the presence of antibodies against SARS-CoV-2 using ID SCREEN® SARS-CoV-2 Double Antigen

multi species ELISA (IDvet, 34790 Grabels, France). To remove non-specific viral inhibitors (thermolabile), the serum samples were heated to 56 °C for 30 min prior to testing.

Nucleic Acids Extraction and PCR

To obtain DNA/RNA from clinical samples and cell cultures, we used a viral RNA/DNA extraction kit (Jena Bioscience, Jena, Germany) according to the manufacturer's instructions. To detect SARS-CoV-2, we used a two-step reaction, performing reverse transcription to obtain cDNA using the SCRIPT cDNA Synthesis Kit (Jena Bioscience, Jena, Germany) in a volume of 20 µL as follows: RNA 4 µL, dNTP 1 µL, reverse transcriptase 0.5 µL, RNase inhibitor 0.5 µL, SCRIPT RT buffer 4 µL, PCR water 8 µL and 2 µL of external primers: Ext. 2019nCoV F 5' – GGCAGTAACCAGAATGGAGA – 3' (positions 28346–28365) and Ext.2019nCoV R 5' – CTCAGTTGCAACCCATATGAT – 3' (positions 28681–28661), forming a 335-bp fragment. The reaction parameters were as follows: 42°C - 10 min; 50°C - 30 min and 70°C for 10 min. After obtaining DNA copies, PCR was performed with 2 µL of internal primers: intF (5'-CACCGCTCTCACTCAACAT-3'), position 28432–28450 and intR (5'-CATAGGGAAGTCCAGCTTCT-3'), position 28643–28624, PCR water 6 µL, 2 µL of cDNA and 10 µL of Hot Start Ruby MasterMix 2x (Jena Bioscience, Jena, Germany) and the following protocol: 30 cycles of denaturation at 95°C - 10 s, annealing at 54.6°C - 20 s and elongation at 72°C - 30 s; final extension at 72°C - 10 min and storage at 10°C. Product size: 212 bp.

We also used the extracted DNA/RNA and the resulting cDNA to perform a differential diagnosis to detect FHV, *Chlamydia felis*, FCV and *Mycoplasma* spp. by PCR [10]. Since the variety of mycoplasma species that infect cats has not yet been fully characterized [31,32], we used primers for *Mycoplasma* spp.

We used PCR water as a negative control for PCR reactions.

Control of the Obtained Nucleic Acids and PCR Products

To control the obtained nucleic acids and PCR products, a NanoDrop 2000 (Thermo Fisher Scientific, Waltham, MA, USA) and gel electrophoresis were used. Gel electrophoresis was performed with 2% agarose (Lonza, USA), 10 ng/mL ethidium bromide (Sigma, USA), 100 mL 1×TAE buffer and a 100-bp DNA marker (Bioline, Meridian, USA) at 130 V, 80 mA for 30 min. The result was observed on a UV transilluminator with a wavelength of 240/260 nm.

Cultivation, Isolation and Detection of SARS-CoV-2 from Cats

The samples were centrifuged at 3000 rpm for 20 min, the supernatant was filtered through a 0.22-µm pore size filter and used for virus cultivation in the VERO E6 cell line, gene clone 76 (obtained from ATCC CRL-1587). The cells were maintained in Dulbecco's Modified Eagle Medium (DMEM) (Sigma-Aldrich, Burlington, MA, USA, Merck, Darmstadt, Germany) low-glucose medium, 20 mM Hepes buffer (Sigma-Aldrich, Merck, Germany). Ten percent fetal calf serum (FCS) (Sigma) was added for cell culture and 5% for maintenance medium. Viruses were propagated in a 24-hour monolayer culture with DMEM maintenance medium (with 4% FBS). For primary isolation, the infected cell cultures were monitored until day 5 from inoculation. Monolayers without cytopathic changes underwent up to 3 consecutive blind passages. For a culture result to be considered positive, the virus must undergo three successful passages with the appearance of a specific cytopathic effect in each of them. Successful passage through three consecutive passages is evidence of the presence of viable virus capable of infecting.. Viral titer was determined using the Reed and Muench method [33]. Cultured human SARS-CoV-2 served as a positive control for the virus isolated from cats. From the obtained isolates, we extracted RNA using the ISOLATE II RNA Mini kit (Bioline, Meridian Bioscience, Memphis, TN, USA) and performed PCR to detect SARS-CoV-2 using the method described above. We used the PCR products obtained to perform sequence analysis.

Sequencing

The procedure was performed as previously described [34]. Enzymatic purification was performed according to the manufacturer’s instructions (Exo-CIP Rapid PCR Cleanup Kit, New England Biolabs, Ipswich, MA, USA) to degrade the residual primers and nucleotides in 1.5-μL aliquots of amplified samples from cell culture. Sequencing was carried out using an internal forward and internal reverse primer (Big Dye Terminator kit, v3.1, Applied Biosystems, Bedford, MA, USA), following the manufacturer’s instructions. To remove residual labeled nucleotides and primers, we used EDTA/sodium citrate/ethanol precipitation. Sequencing results were read on an automated capillary sequencing instrument (ABI 3500xl, Applied Biosystems, Bedford, MA, USA).

The obtained sequences were processed and identified using MEGAX [35] and BLAST NCBI (National Center for Biotechnology Information, Bethesda, MD, USA), respectively.

Statistics/Data Analysis

Demographic analysis included sex and age distribution; positives for SARS-CoV-2 only; negatives for SARS only; negatives in all assays; mixed SARS-CoV-2 infections with one, two or more other causative agents; distribution of other infections with and without SARS.

3. Results

We performed demographic analysis of the cats tested for SARS-CoV-2 between Jan 5 and Dec 17, 2023 (Table 1).

Table 1. Sex and age demographic distribution of 102 cats tested for SARS-CoV-2 in the period of Jan 5–Dec 17, 2023.

Age	Variable	Value
	Sample size	71
	Lowest value	0.17
	Highest value	18.000
	Arithmetic mean	4.36
	95% CI for the mean	3.37–5.34
	Median	3.000
	95% CI for the median	2.00–5.00
	Variance	17.34
	Standard deviation	4.16
	Relative standard deviation	95.61%
	Standard error of the mean	0.49
	Coefficient of skewness	1.02 (P = 0.0011)
	Coefficient of kurtosis	0.41 (P = 0.3761)
	Shapiro–Wilk test	W=0.8715
	for Normal distribution	Rejected (P < 0.0001)
Sex distribution		
	Sex	Number Percent (%)
	Female (f)	53 52
	Male (m)	49 48
	Total	102 100

*Data show median values instead of arithmetic means due to uneven age distribution.

The study included a total of 102 samples from symptomatic cats meeting the inclusion criteria: redness in the oral cavity, nasal discharge and eye discharge. The fecal samples were not tested due to the lack of patients that met the eligibility criteria.

The PCR results showed that 31 out of the 102 cats, or 30.39%, tested negative for all pathogens: 12 females and 19 males with an average age of 2 years (min. 0.5 – max. 9). There were 20 positive samples for FHV (19.6%), 17 for *Chl. felis* (16.7%) and 61 for mycoplasma (59.8%). The cats that were positive for SARS-CoV-2 were 21 or 20.6% (15 females and 6 males), (Table 2). Differential diagnosis identified 17 SARS-CoV-2-positive cases (80.95%) with a mixed infection with some of the other disease-causing agents (Table 2). We also detected co-infections without SARS-CoV-2 involvement – 16 cases (Table 3), with a total of 33 cases (46.49%) of co-infection among all 71 positive cases. FCV was not detected in the 102 samples tested here. Only 19% of the SARS-CoV-2 positive samples (from 1 male and 3 female cats) met the criteria for virus isolation and had clinical manifestations of standalone SARS-CoV-2 infection.

Table 2. Statistical analysis of cats tested in 2023 with standalone SARS-CoV-2 infection and co-infection with FHV, FCV, mycoplasma and *Chl.felis*. .

SARS-CoV-2 status	Number	Percent (%)
Negative	81	79.4
Positive	21	20.6
Total	102	100
Statistic	Value	
Chi-squared (χ^2)	34.127	
Degrees of freedom (DF)	1	
Significance level	P < 0.0001	

Types of co-infections among SARS-CoV-2–positive cats		
Infection type	Number	Percent (%)
SARS-CoV-2 + Mycoplasma spp.	8	38.1
SARS-CoV-2 + Mycoplasma spp. + C. felis	2	9.5
SARS-CoV-2 + Mycoplasma spp. + FHV	2	9.5
SARS-CoV-2 + Mycopl spp. + FHV + C. felis	5	23.8
SARS-CoV-2 only	4	19
Total	21	100
Statistic	Value	
Chi-squared (χ^2)	5.905	
Degrees of freedom (DF)	4	
Significance level	P = 0.2064	

Table 3. Identified co-infections without SARS-CoV-2 involvement in 102 clinical samples from cats in 2023.

Type of co-infection	Number	Percent
C.felis+Mycopl.spp	3	18.75%
FHV+C.felis	4	25.00%
FHV+C.felis+Mycopl.spp	3	18.75%
FHV+Mycopl.spp.	6	37.50%

Total	16	100.00%
-------	----	---------

Our survey of the owners of the 21 SARS-CoV-2-positive cats showed that 14 of the cats were kept indoors and had no contact with other cats, four had outdoor access, and three owners did not respond. None of the owners or members of their families had had a current confirmed SARS-CoV-2 infection. Five owners reported a mild respiratory illness in the family with no tests performed, about 17-20 days before illness onset in the cats. Off the record, all owners reported being immune after the pandemic as a result of vaccination or previous illness.

History and clinical presentation of cats with standalone SARS2: On Apr 8, 2023, the owners of Cat 1 (reg. no. 270/080423), a 2.5-year-old female weighing 3 kg, visited a veterinary clinic because of serous discharge from the eyes. Cat 2 (reg. No. 271/110423), male, 1 year old, 5 kg, was admitted to the clinic on Apr 11, 2023, for castration, when examination revealed slight serous discharge from the eyes. On Apr 20, 2023, the owner of female Cat 3 (reg. no. 276/200423), aged 10 months, weighing 4 kg, visited the same clinic due to serous discharge from the eyes (Figure 1). On Sep 27, another patient (Cat 4), a 3-year-old female, also with discharge from the eyes, was admitted to the clinic.




Figure 1. Serous discharge from the medial eye corner of both eyes of Cat 2 (*left*) and serous discharge from the left medial eye corner of Cat 3 (*right*).

Medical history reported by the owners showed that the cats were kept indoors, i.e., they had no contact with the outdoor environment; there were no family members with COVID-19 symptoms; the owners of two of the cats had received three doses of vaccine (last dose in 2022), and the owner of the third cat had recovered from the disease in 2022 with an antibody titer of 655 BAU/mL (detected on Mar 8, 2023, doc. No. 8390202). The owners of Cat 4 did not provide information about their immune status.

The clinical examinations of the four cats showed no changes in their general condition. The body temperature, puls, and respiration were within reference values. There was only serous secretion from the medial eye corner (Figure 1).

Analysis of blood parameters in all four cats showed values within the normal ranges: WBC from 2.9 to $8.8 \times 10^9/L$, Lymph. $1.1 - 4.7 \times 10^9/L$, Mon. $0.2-0.3 \times 10^9/L$, Gran. $1.6-3.8 \times 10^9/L$, HGB $107-153$ g/L, HCT $33.7-38.4\%$ and Eos. $21.3-29.8\%$. Erythrocytes (RBC) ranged from $6.92 \times 10^{12}/L$ to $9.52 \times 10^{12}/L$.

The swab samples from the cats tested positive for SARS-CoV-2 by PCR while those from the owners tested negative. Serological samples from the cats taken during the illness were positive for antibodies against SARS-CoV-2. Serological tests performed on the owners of Cat 1 and Cat 4 showed the presence of IgG antibodies only, while the owners of Cat 2 and Cat 3 were weakly positive for IgM in addition to IgG (a weaker band compared to the control and IgG antibodies).

The PCR tests of the samples from the four cats gave negative results for FHV, FCV, *Mycoplasma* spp. and *Chlamydia felis*.

Treatment of standalone SARS2 included Viusid 2×1 mL per 5 kg of body weight, R X Immunosupport 1 capsule daily, Vetomun 1 capsule daily and Lisymun 2×0.5 mL for up to 2.5 kg

body weight and 2×1 mL for 2.5–5 kg kittens. The second PCR test performed 10 days after the diagnosis showed negative results. The same therapy was applied to the treatment of cases associated with co-infection. The duration of administration of these preparations was 1–3 months, depending on the severity of the disease.

Propagation of the four samples on the VERO E6 cell line resulted in characteristic CPE (Figure 2).




Figure 2. Cytopathic effect of four SARS-CoV-2 isolates from cats, a positive control from a human isolate, and cell culture control 48 hours after infection. A) Cat isolate 1; B) Cat isolate 2; C) Cat isolate 3; D) Cat isolate 4; E) Control isolate; F) Cell culture (negative) control.

The viral isolates showed the following titers: Isolate 1 – $10^{4.67}$ TCID₅₀/0.2 mL; Isolate 2 – $10^{4.5}$ TCID₅₀/0.2 mL; Isolate 3 – $10^{5.5}$ TCID₅₀/0.2 mL; and Isolate cat 4 – $10^{5.67}$ TCID₅₀/0.2 mL.

To confirm SARS-CoV-2, we performed PCR on the isolates and sequenced the resulting 212 bp products (Figure 3). Sequence alignment in MEGAX and analysis via BLAST NCBI confirmed that the isolates were SARS-CoV-2.




Figure 3. PCR analysis for confirmation of SARS-CoV-2 isolates from cell cultures from four cats positive only for the virus. 1) Negative control; 2) Sample from Cat 1; 3) Sample from Cat 2; 4) Sample from Cat 3; 5) Sample from Cat 4; 6) 50-bp DNA ladder (Bioline).

4. Discussion

The results showed a prevalence of SARS-CoV-2 in 20.6% (21/102) of upper respiratory tract infections. In 81% of these cases, there were co-infections with FHV, *Mycoplasma* and *Chl. felis*. There was a standalone SARS-CoV-2 infection in four cats, and we obtained virus isolates from them to test for the presence of infectious SARS-CoV-2 virions and to help determine the possibility for infectious virus spreading from cats.

According to Fisher’s theory [36], the random distribution of infection between the sexes is 50:50, and this also applies to domestic cats [37].

Our results correlate with these data, with a difference of 2% (48% male cats). This is in agreement with other reports that female cats predominate slightly over males, with a difference of 4% between the sexes [25,38].

Previous serological studies of domestic and stray cats have shown no statistical relationship between sex and the risk of SARS-CoV-2 infection [8,10,28,39]. Some authors have reported higher SARS-CoV-2 prevalence in female cats in serological assays [40] and antigen tests [27], while others in males [41,42]. Our results showed that the cases of SARS-CoV-2 infection were 2-fold higher among female cats as compared to males. In our study, the difference in the number of samples between the two sexes (52% female vs. 48% male) as influence on this result was smaller compared to Tyson et al. [42], with a distribution of 53% male, 39% female and 8% unidentified. Probably behavioral factors, such as more frequent interaction with humans, may play a major role, rather than a difference in the biological susceptibility to the virus [40,42].

In cases of SARS-CoV-2 and FHV co-infection, there is probably reactivation of the herpesvirus as a result of SARS-CoV-2 infection [26], which leads to immune system suppression in various ways. For example, there is evidence that low levels of SARS-CoV-2 N protein suppress the innate immune response by reducing RIG-I ubiquitination through interaction with TRIM25, and reducing STAT1/STAT2 phosphorylation and nuclear translocation [43], and also disrupt the antiviral response by inhibiting all key stages of IFN defense [44]. It may also be the result of reactivation or recent infection, in connection with the above. Mycoplasmas cause endogenous infections, but since their virulent characteristics are not well established, it is not possible to rule out external transmission completely. Mycoplasmas can act as secondary agents when the host’s defenses weaken as a result of infection with viruses, bacteria or other causes [31]. Thus, infection with SARS-CoV-2 may ‘predispose’ the host and potentiate the development of mycoplasma infection through its negative effect on the immune system, as described above.

According to the general understanding, natural transmission of chlamydial infections occurs through objects and close contact with other affected animals and their aerosols [31]. Chlamydial

infections in cats may not be associated with SARS-CoV-2, but may have an impact on the subsequent development of the infection for the reasons already mentioned.

Approximately one-third of the cats tested negative for the pathogens under investigation, potentially indicating that the clinical signs may have developed as a result of other microorganisms, such as *Pasteurella*, *Streptococcus*, *Staphylococcus*, *Pseudomonas*, *E. coli*, *Bordetella*, *Cryptococcus*, *Aspergillus* [45–47] or non-infectious causes such as allergies [48,49]. To investigate this, other tests such as standard microbiology and allergen tests need to be performed.

Direct detection of SARS-CoV-2 (antigen or RNA) varies in street cats from 0.5% [25] to 23.60% [27]. In our study, the domestic cats showed 20.6% positive samples, which corresponds to the possibility of contact between the domestic cat and its infected owner [26]. Hosie et al. [26], based on the prevalence of SARS-CoV-2 in humans in the UK for the period March-June 2020 (5%), estimate that 19 out of the 386 cat samples tested belong to households affected by COVID-19, with the authors detecting only one positive sample. In our study, for five of the SARS-CoV-2-positive cats, there was evidence of a respiratory infection in the owners 17–20 days prior. On this basis described above, we can consider infections in cats as a manifestation of SARS-CoV-2 infection in humans and a potential indicator of a past asymptomatic or undiagnosed SARS-CoV-2 infection in the family. Our estimate is that about 20% of the owners of the cats studied had had a SARS-CoV-2 infection, while the official data for humans for 2023 range from 3 to 16% [50]. As the post-pandemic demand for testing and, accordingly, the number of people tested was low [50], we speculate that the prevalence was higher and correlated with the data for cats. The owners of all SARS-CoV-2-positive cats were clinically healthy at the time of the study. This, however, does not rule out the possibility that they were asymptomatic or oligosymptomatic carriers of the virus.

On the basis of our observations and those of other authors, we can summarize that the clinical picture of SARS-CoV-2 in cats is associated with asymptomatic [19], mild disease and symptoms such as sneezing [20], digestive signs, apathy and appetite reduction, fever, upper respiratory tract involvement [9] and serous secretions from the medial eye corner, gastrointestinal symptoms [21] or complications such as hypertrophic cardiomyopathy [22], myocarditis, pneumonia [23] and bronchial pneumonia [19]. The transmission of SARS-CoV-2 from humans to cats has been proven in owners infected with the virus: indirectly via detection of antibodies in their cats and directly via detection of the virus in the cats [8,13,28]. Viral RNA can remain detectable in cats infected with SARS-CoV-2 for up to 17 days [13]. Detection of viral nucleic acid by PCR does not indicate that the infected host is the source of infectious virus and can spread the virus. There is evidence that a SARS-CoV-2 positive PCR result does not always result in virus isolation [11]. Studies show that virus transmission is possible to occur from cat to cat [9]. In cases of natural infection, there is evidence that antibodies are not detected three months after infection [9], indicating that a cat can become reinfected with the virus. This, along with the prolonged spread, makes it possible for the virus to circulate in certain cat populations (large numbers over a wide area). In this respect, studies discuss the possibility of cats infecting humans and their role in the spread and epidemiology of the virus [9,13,29,40,51,52].

Viruses are not naturally adapted to laboratory cell cultures used for virus isolation. Viruses need to adapt to the respective cell culture, via corresponding mutations in the viruses [53–55]. Isolation of a virus in laboratory conditions demonstrates that the sample contains a sufficient infectious viral load to infect susceptible hosts, thus reflecting the natural adaptation of the virus to these species. Our study showed that SARS-CoV-2-positive cats are sources of infection, as the virus was isolated from all four positive animals. This is the first component of the Gromashevsky [56] triad—the presence of a source of an infectious agent. The second component, the susceptible host, includes humans and other cats that may be exposed to the virus. The third component, the environment, is relatively constant in homes and facilitates interaction between the agent and the susceptible host, creating conditions for potential transmission of the infection to both humans and other cats.

Two of the cats from which we isolated the virus had owners who showed only IgG antibodies. These antibodies may be post-infectious or post-vaccination. The weakly positive result for IgM

antibodies in two of the owners is probably due to a fading initial secondary immune response to SARS-CoV-2. The virus transmission occurred probably from the owners to the cats. It is less likely that the cats had acquired the infection in another way, such as through contaminated shoes of the owners or guests. It is also possible for the virus transmission to occur from cat to cat [9]. In such cases, the cat can transmit the virus to the owner. If the owner does not have post-infectious immunity with IgA [57], a local infection can develop, which is what the SARS-CoV-2 infection has become.

Although the infection has a mild clinical course in cats, preparations such as Viusid, R X Immunosupport, Vetomun and Lisymun can support the immune response owing to their antioxidant and immunomodulatory (stimulating) properties. The second PCR, 10 days after the infection onset, did not detect the virus, and there were no clinical signs. This suggests that the therapy could have a potential effect on virus elimination and on the period of shedding. However, the present study does not allow us to establish a definitive causal relationship.

It is important for owners to limit their cats' contact with shoes and clothing worn outdoors and to wash their hands before touching their pets. The study of domestic cats in the SARS-CoV-2 post-pandemic period is important for the differential diagnosis of the causal agents of conjunctivitis and upper respiratory tract diseases, as well as for understanding the movement and spread of the virus in the environment close to humans.

The ELISA method used in our study does not distinguish between different classes of antibodies and therefore does not provide information about current or past infection. In this regard, the method can find application as an additional test in cases of suspected SARS-CoV-2 infection shortly after infection (as antibodies are not detected at 3 months [9]).

The study has some limitations. The owners did not give permission for taking follow-up blood samples from their cats (20 days later) to test for the presence of antibodies against SARS-CoV-2, to demonstrate seroconversion, or for subsequent samples to study the dynamics of the immune response. Also, fecal samples were not tested due to the lack of patients that met the eligibility criteria. Therefore, we were unable to test for shedding through feces and to assess the role of such shedding in environmental contamination and virus spread.

5. Conclusions

This study showed that domestic cats can shed infectious SARS-CoV-2, even with minimal clinical signs, and indoor owners were the possible source of infection. The results highlight the role of cats as potential sources of infection and contribute to the understanding of the movement and spread of SARS-CoV-2 in domestic environment. The reported observations also contribute to the differential diagnosis of respiratory and ophthalmic diseases in cats. The results from immunotherapy indicated a potential effect on the immune response in post-pandemic SARS-CoV-2 infection.

This single-center study demonstrates that infectious SARS-CoV-2 can be isolated from symptomatic domestic cats during the post-pandemic period. Most PCR-positive cats had co-infections with other respiratory pathogens. Clinical signs were mild. Further controlled and longitudinal studies are required to determine the epidemiological significance and clinical impact of feline SARS-CoV-2 infection.

Supplementary Materials: Not provided.

Author Contributions: "Conceptualization, I.S.; methodology, I.S. and K.S.; software, N.R. and A.R.; validation, I.S., M.K., K.S., K.M. and B.S.; formal analysis, I.S., M.K.; investigation, I.S., K.S., K.M., B.S., A.R.; resources, I.S. and M.K.; data curation, M.K., S.S. and I.S.; writing—original draft preparation, I.S. and K.S.; writing—review and editing, N.R., M.K., A.R., S.S., I.S. and K.S.; visualization, I.S., K.S., A.R. and N.R.; supervision, S.S. and A.R.; project administration, I.S.; funding acquisition, I.S. All authors have read and agreed to the published version of the manuscript." Please turn to the CRediT taxonomy for the term explanation. Authorship must be limited to those who have contributed substantially to the work reported.

Funding: “This research was funded by privet veterinary clinic “BayVet”, Sofia, and Ivo Sirakov.

Institutional Review Board Statement: “Not applicable”. The investigations are part of the diagnostic process.

Informed Consent Statement: “Informed consent was obtained from all subjects involved in the study.”.

Data Availability Statement: The original contributions presented in this study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author(s).

Acknowledgments: The authors express their gratitude to “BayVet” - Sofia for providing the samples and funding the studies.

Conflicts of Interest: “The authors declare no conflicts of interest.”.

Abbreviations

The following abbreviations are used in this manuscript:

FHV	<i>Feline herpesvirus</i>
FCV	<i>Feline calicivirus</i>
PCR	Polymerase chain reaction
CPE	Cytopatological effect
URT	Upper respiratory tract
RNA	Ribonucleic acid
DNA	Deoxyribonucleic acid
ELISA	Enzyme-Linked Immunosorbent Assay
TRIM25	Tripartite Motif Containing 25

References

1. Kim, Y.-I.; Kim, S.-G.; Kim, S.-M.; Kim, E.-H.; Park, S.-J.; Yu, K.-M.; Chang, J.-H.; Lee, S.; Casel, M.A.B.; Um, J.; et al. Infection and rapid transmission of SARS-CoV-2 in ferrets. *Cell Host Microbe* **2020**, *27*, 704–709.e2.
2. Shi, J.; Wen, Z.; Zhong, G.; Yang, H.; Wang, C.; Huang, B.; Liu, R.; He, X.; Shuai, L.; Sun, Z.; et al. Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-CoV-2. *Science* **2020**, *368*, 1016–1020.
3. Abdel-Moneim, A.S.; Abdelwhab, E.M. Evidence for SARS-CoV-2 infection of animal hosts. *Pathogens* **2020**, *9*, 529.
4. Bosco-Lauth, A.M.; Hartwig, A.E.; Porter, S.M.; Gordy, P.W.; Nehring, M.; Byas, A.D.; VandeWoude, S.; Ragan, I.K.; Maison, R.M.; Bowen, R.A. Experimental infection of domestic dogs and cats with SARS-CoV-2. *Proc. Natl. Acad. Sci. USA* **2020**, *117*, 26382–26388.
5. Chaintoutis, S.C.; Siarkou, V.I.; Mylonakis, M.E.; Kazakos, G.M.; Skeva, P.N.; Bampali, M.; Dimitriou, M.; Dovrolis, N.; Polizopoulou, Z.S.; Karakasiliotis, I.; Dovas, C.I. Limited cross-species transmission and absence of mutations associated with SARS-CoV-2 adaptation in cats. *Transbound. Emerg. Dis.* **2022**, *69*, 1606–1616.
6. Meza-Robles, C.; Barajas-Saucedo, C.E.; Tiburcio-Jimenez, D.; Mokay-Ramírez, K.A.; Melnikov, V.; Rodriguez-Sanchez, I.P.; Martinez-Fierro, M.L.; Garza-Veloz, I.; Zaizar-Fregoso, S.A.; Guzman-Esquivel, J.; et al. One-step nested RT-PCR for COVID-19 detection: A flexible, locally developed test for SARS-CoV-2 nucleic acid detection. *J. Infect. Dev. Ctries.* **2020**, *14*, 679–684. <https://doi.org/10.3855/jidc.12726>.
7. Marinova, L.; Gaitanevska, I.; Penchev, D.; Korsun, N.; Christova, I. Overview of the COVID-19 pandemic and its impact on the morbidity in the Sofia city region during 2020–2021. *Probl. Infect. Parasit. Dis.* **2023**, *50*, 19–25. <https://doi.org/10.58395/pipd.v50i2.91>.
8. Daigle, L.; Khalid, H.; Gagnon, C.A.; et al. High prevalence of SARS-CoV-2 antibodies and low prevalence of SARS-CoV-2 RNA in cats recently exposed to human cases. *BMC Vet. Res.* **2024**, *20*, 304. <https://doi.org/10.1186/s12917-024-04150-4>.
9. Barroso, R.; Vieira-Pires, A.; Antunes, A.; Fidalgo-Carvalho, I. Susceptibility of Pets to SARS-CoV-2 Infection: Lessons from a Seroepidemiologic Survey of Cats and Dogs in Portugal. *Microorganisms* **2022**, *10*,345. <https://doi.org/10.3390/microorganisms10020345>

10. Sirakov, I.; Popova-Ilinkina, R.; Ivanova, D.; Rusenova, N.; Mladenov, H.; Mihova, K.; Mitov, I. Development of Nested PCR for SARS-CoV-2 Detection and Its Application for Diagnosis of Active Infection in Cats. *Vet. Sci.* **2022**, *9*, 272. <https://doi.org/10.3390/vetsci9060272>
11. Shishkova, K.; Sirakova, B.; Shishkov, S.; Stoilova, E.; Mladenov, H.; Sirakov, I. A Comparative Analysis of Molecular Biological Methods for the Detection of SARS-CoV-2 and Testing the In Vitro Infectivity of the Virus. *Microorganisms* **2024**, *12*, 180. <https://doi.org/10.3390/microorganisms12010180>
12. Case, J.B.; Bailey, A.L.; Kim, A.S.; Chen, R.E.; Diamond, M.S. Growth, detection, quantification, and inactivation of SARS-CoV-2. *Virology* **2020**, *548*, 39–48.
13. Neira V, Brito B, Agüero B, Berrios F, Valdés V, Gutierrez A. A household case evidences shorter shedding of SARS-CoV-2 in naturally infected cats compared to their human owners. *Emerg Microbes Infect* **2021**; *10* (1), 376–383.
14. Zhang, Q.; Zhang, H.; Gao, J.; Huang, K.; Yang, Y.; Hui, X.; He, X.; Li, C.; Gong, W.; Zhang, Y.; Zhao, Y. A serological survey of SARS-CoV-2 in cats in Wuhan. *Emerg. Microbes Infect.* **2020**, *9*, 2013–2019.
15. Klaus, J.; Zini, E.; Hartmann, K.; Egberink, H.; Kipar, A.; Bergmann, M.; Palizzotto, C.; Zhao, S.; Rossi, F.; Franco, V.; et al. SARS-CoV-2 infection in dogs and cats from southern Germany and northern Italy during the first wave of the COVID-19 pandemic. *Viruses* **2021**, *13*, 1453. <https://doi.org/10.3390/v13081453>.
16. Jairak, W.; Charoenkul, K.; Chamsai, E.; Udom, K.; Chaiyawong, S.; Hangsawek, A.; Waenkaew, S.; Mungaomklang, A.; Tangwangvivat, R.; Amonsin, A.; et al. Survey of SARS-CoV-2 in dogs and cats in high-risk areas during the second wave of COVID-19 outbreak, Thailand. *Zoonoses Public Health* **2022**, *69*, 737–745. <https://doi.org/10.1111/zph.12907>.
17. Thongyuan, S.; Thanongsaksrikul, J.; Srimanote, P.; Phongphaew, W.; Eiamcharoen, P.; Thengchaisri, N.; Bosco-Lauth, A.; Decaro, N.; Yodsheewan, R. Seroprevalence of anti-SARS-CoV-2 antibodies in cats during five waves of COVID-19 epidemic in Thailand and correlation with human outbreaks. *Animals* **2024**, *14*, 761. <https://doi.org/10.3390/ani14050761>
18. Sirakov, I.; Rusenova, N.; Rusenov, A.; Gergova, R.; Strateva, T. Human ELISA detects anti-SARS-CoV-2 antibodies in cats: Seroprevalence and risk factors for virus spread in domestic and stray cats in Bulgaria. *Vet. Sci.* **2023**, *10*, 42. <https://doi.org/10.3390/vetsci10010042>.
19. Natale, A.; Mazzotta, E.; Mason, N.; Ceglie, L.; Mion, M.; Stefani, A.; Fincato, A.; Bonfante, F.; Bortolami, A.; Monne, I.; Bellinati, L. SARS-CoV-2 natural infection in a symptomatic cat. Diagnostic, Clinical and Medical Management in a One Health Vision *Animals* **2021**, *11*, 1640.
20. Sila, T.; Sunghan, J.; Laochareonsuk, W.; et al. Suspected cat-to-human transmission of SARS-CoV-2, Thailand, July–September 2021. *Emerg. Infect. Dis.* **2022**, *28*, 1485–1488.
21. Sailleau, C.; Dumarest, M.; Vanhomwegen, J.; Delaplace, M.; Caro, V.; Kwasiborski, A.; Hourdel, V.; Chevaillier, P.; Barbarino, A.; Comtet, L.; et al. First detection and genome sequencing of SARS-CoV-2 in an infected cat in France. *Transbound. Emerg. Dis.* **2020**, *67*, 2324–2328.
22. Carvallo, F.R.; Martins, M.; Joshi, L.R.; Caserta, L.C.; Mitchell, P.K.; Cecere, T.; Hancock, S.; Goodrich, E.L.; Murphy, J.; Diel, D.G. Severe SARS-CoV-2 infection in a cat with hypertrophic cardiomyopathy. *Viruses* **2021**, *13*, 1510.
23. Keller, M.; Hagag, I.T.; Balzer, J.; Beyer, K.; Kersebohm, J.C.; Sadeghi, B.; Wernike, K.; Höper, D.; Wylezich, C.; Beer, M.; Groschup, M.H. Detection of SARS-CoV-2 variant B.1.1.7 in a cat in Germany. *Res. Vet. Sci.* **2021**, *140*, 229–232.
24. Panei CJ, Bravi ME, More G, De Felice L, Unzaga JM, Salina M, Rivero FD, Di Lullo D, Pecoraro M, Alvarez D, Castro E. Serological evidence of SARS-CoV-2 infection in pets naturally exposed during the COVID-19 outbreak in Argentina. *Veterinary Immunology and Immunopathology* **2022**, *254*, 110519.
25. Bellinati, L.; Campalto, M.; Mazzotta, E.; Ceglie, L.; Cavicchio, L.; Mion, M.; Lucchese, L.; Salomoni, A.; Bortolami, A.; Quaranta, E.; et al. One-Year Surveillance of SARS-CoV-2 Exposure in Stray Cats and Kennel Dogs from Northeastern Italy. *Microorganisms* **2023**, *11*, 110. <https://doi.org/10.3390/microorganisms11010110>
26. Hosie, M.J.; Epifano, I.; Herder, V.; Orton, R.J.; Stevenson, A.; Johnson, N.; et al. Detection of SARS-CoV-2 in respiratory samples from cats in the UK associated with human-to-cat transmission. *Vet. Rec.* **2021**, e247. <https://doi.org/10.1002/vetr.247>.

27. Santos, R.S.; Lee, D.A.B.; Barreto, M.D.S.; Silva, E.E.D.; de Jesus, P.C.; Moura, P.H.M.; Silva, D.M.R.R.; de Souza, J.B.; Bezerra, T.L.; Santos, P.O.M.; et al. Rapid antigen detection of SARS-CoV-2 in stray cats. *Vet. World* **2024**, *17*, 1611–1618. <https://doi.org/10.14202/vetworld.2024.1611-1618>.

28. Michelitsch, A.; Allendorf, V.; Conraths, F.J.; Gethmann, J.; Schulz, J.; Wernike, K.; Denzin, N. SARS-CoV-2 infection and clinical signs in cats and dogs from confirmed positive households in Germany. *Viruses* **2023**, *15*, 837.

29. Sirakov I, Stankova P, Bakalov D. Retrospective Analysis of the Spread of SARS-CoV-2 in the Mediterranean Part of Bulgaria, During the First Wave of the Pandemic. *J Pure Appl Microbiol* **2024**, *18*(1), 438-450.

30. Thieulent CJ, Carossino M, Peak L, Wolfson W, Balasuriya UB. Development and validation of multiplex one-step qPCR/RT-qPCR assays for simultaneous detection of SARS-CoV-2 and pathogens associated with feline respiratory disease complex. *PLoS One* **2024**, *19*(3), e0297796.

31. Eissa, N. Mycoplasma, rickettsia, and chlamydia diseases of dogs and cats. In *Introduction to Diseases, Diagnosis, and Management of Dogs and Cats*; Academic Press: Cambridge, MA, USA, **2024**; pp. 489–499.

32. Spargser, R.; Rosengarten, R. Identification and differentiation of canine *Mycoplasma* isolates by 16S–23S rDNA PCR-RFLP. *Vet. Microbiol.* **2007**, *125*, 170–174.

33. Reed, L.J.; Muench, H. A simple method of estimating fifty percent endpoints. *Am. J. Hyg* **1938**, *27*, 493–497.

34. Sirakov I, Popova R, Alexandar I, Marinova-Petkova A. GENETIC VARIATIONS IN THE STX1 AND EAE GENES OF BULGARIAN MILK ESCHERICHIA COLI ISOLATES. *Comptes rendus de l'Académie bulgare des Sciences* **2013**, *66*(7), 1019-1024.

35. Kumar, S.; Stecher, G.; Li, M.; Knyaz, C.; Tamura, K. MEGA X: Molecular evolutionary genetics analysis across computing platforms. *Mol. Biol. Evol.* **2018**, *35*, 1547–1549.

36. Fisher, R.A. *The Genetical Theory of Natural Selection*, 2nd ed.; Dover Publications: New York, NY, USA, 1958.

37. McDonald, J.; Finka, L.; Foreman-Worsley, R.; Skillings, E.; Hodgson, D. Empirical modelling of *Felis catus* population dynamics in the UK. *PLoS ONE* **2023**, *18*, e0287841. <https://doi.org/10.1371/journal.pone.0287841>.

38. Say, L. Système d'appariement et succès de reproduction chez le chat domestique (*Felis catus* L.): Conséquence sur la distribution de la variabilité génétique. In *Conference proceedings / book chapter*; **2000**; pp. 369–375.

39. Agüero, B.; Tischler, N.D.; Alegria, R.; Cárdenas-Cáceres, S.; Berríos, F.; Espinoza, P.; Neira, V. Longitudinal study on SARS-CoV-2 antibody responses in companion animals, Chile. *Vet. Q.* **2025**, *45*, 1–12.

40. Ulloa A, Cordero-Ortiz M, Jara LM, Schiaffino F, Ferradas C, Sánchez-Carrión C, Martínez-Vela A, Hernández J, Giménez-Lirola LG. High seroprevalence of SARS-CoV-2 in cats linked to human infection in a Latin American country with elevated COVID-19 transmission and mortality. *Frontiers in Veterinary Science* **2025**, *12*, 1503000.

41. Moutinho, I.; Henriques, M.; Cardoso, S.; da Penha Coutinho, T.; Penha-Gonçalves, C.; Demengeot, J.; Aires-da-Silva, F. SARS-CoV-2 seroprevalence in indoor house cats from Lisbon. *Transbound. Emerg. Dis.* **2024**, 1543922.

42. Tyson, G.B.; Jones, S.; Montreuil-Spencer, C.; Logan, N.; Scott, S.; Sasvari, H.; Hosie, M.J. Increase in SARS-CoV-2 seroprevalence in UK domestic felids. *Viruses* **2023**, *15*, 1661.

43. Zhao, Y.; Sui, L.; Wu, P.; et al. Dual role of SARS-CoV-2 nucleocapsid protein in regulating innate immune response. *Signal Transduct. Target. Ther.* **2021**, *6*, 331. <https://doi.org/10.1038/s41392-021-00742-w>

44. Gusev, E.; Sarapultsev, A.; Solomatina, L.; Chereshevnev, V. SARS-CoV-2-specific immune response and the pathogenesis of COVID-19. *Int. J. Mol. Sci.* **2022**, *23*, 1716. <https://doi.org/10.3390/ijms23031716>.

45. Adler, K.; Radeloff, I.; Stephan, B.; Greife, H.; Hellmann, K. Bacteriological and virological status in upper respiratory tract infections of cats (cat common cold complex). *Berl. Munch. Tierarztl. Wochenschr.* **2007**, *120*, 120–125.

46. Frymus, T.; Addie, D.D.; Boucraut-Baralon, C.; Egberink, H.; Gruffydd-Jones, T.; Hartmann, K.; Horzinek, M.C.; Hosie, M.J.; Lloret, A.; Lutz, H.; Marsilio, F.; Pennisi, M.G.; Radford, A.D.; Thiry, E.; Truyen, U.; Möstl,

- K. Streptococcal infections in cats: ABCD guidelines on prevention and management. *J. Feline Med. Surg.* **2015**, *17*, 620–625. <https://doi.org/10.1177/1098612X15588454>
47. Egberink, H.; Addie, D.; Belák, S.; Boucraut-Baralon, C.; Frymus, T.; Gruffydd-Jones, T.; Hartmann, K.; Hosie, M.J.; Lloret, A.; Lutz, H.; Marsilio, F.; Pennisi, M.G.; Radford, A.D.; Thiry, E.; Truyen, U.; Horzinek, M.C. Bordetella bronchiseptica infection in cats: ABCD guidelines on prevention and management. *J. Feline Med. Surg.* **2009**, *11*, 610–614. <https://doi.org/10.1016/j.jfms.2009.05.010>
 48. Mueller, A. Allergic conjunctivitis: An update. In *Allergic Diseases—From Basic Mechanisms to Comprehensive Management and Prevention*; Springer International Publishing: Cham, Switzerland, **2021**; pp. 95–99.
 49. Reed, N. Chronic rhinitis in the cat. *Vet. Clin. North Am. Small Anim. Pract.* **2014**, *44*, 33–50.
 50. National Center of Infectious and Parasitic Diseases (NCIPD). Information on COVID-19. Available online: https://www1.ncipd.org/index.php?option=com_k2&view=item&id=546:ncov-012020&Itemid=1105&lang=bg (accessed on October **2025**).
 51. Allendorf, V.; Denzin, N.; Conraths, F.J.; Boden, L.A.; Elvinger, F.; Magouras, I.; Stegeman, A.; Wood, J.L.; Urueña, A.C.; Grace, K.E.; Stärk, K.D.C. Does having a cat in your house increase your risk of catching COVID-19? *One Health* **2022**, *14*, 100381.
 52. Sila, T.; Sunghan, J.; Laochareonsuk, W.; Surasombatpattana, S.; Kongkamol, C.; Ingviya, T.; Siripaitoon, P.; Kositpantawong, N.; Kanchanasuwan, S.; Hortiwakul, T.; Charernmak, B.; Nwabor, O.F.; Silpapojakul, K.; Chusri, S. Suspected cat-to-human transmission of SARS-CoV-2, Thailand, July–September 2021. *Emerg. Infect. Dis.* **2022**, *28*, 1485–1488. <https://doi.org/10.3201/eid2807.212605>
 53. Frericks, N.; Brown, R.J.P.; Reinecke, B.M.; Herrmann, M.; Brüggemann, Y.; Todt, D.; Miskey, C.; Vondran, F.W.R.; Steinmann, E.; Pietschmann, T.; Sheldon, J. Hepatitis C virus cell culture adaptive mutations enhance cell culture propagation by multiple mechanisms but boost antiviral responses in primary human hepatocytes. *bioRxiv* **2023**, 2023.11.22.568224. <https://doi.org/10.1101/2023.11.22.568224>
 54. Carrascosa-Sàez, M.; Marqués, M.-C.; Geller, R.; Elena, S.F.; Rahmeh, A.; Dufloo, J.; Sanjuán, R.; The IBV-COVID19-Pipeline Consortium. Cell type-specific adaptation of the SARS-CoV-2 spike. *Virus Evol.* **2024**, *10*, veae032. <https://doi.org/10.1093/ve/veae032>
 55. Yan, X.-L.; Li, J.; Ma, Q.-Q.; Wang, H.-J.; Li, L.; Zhao, H.; Qin, C.-F.; Li, X.-F. Identification of mutations in viral proteins involved in cell adaptation using a reverse genetic system of the live attenuated hepatitis A virus vaccine H2 strain. *Viol. Sin.* **2024**, *39*, 882–891.
 56. Gromashevsky, L.V. *General Epidemiology*; Meditsina: Moscow, USSR, **1949**.
 57. Ma H, Zeng W, He H, Zhao D, Yang Y, Jiang D, Qi PY, He W, Zhao C, Yi R, Wang X. COVID-19 diagnosis and study of serum SARS-CoV-2 specific IgA, IgM and IgG by chemiluminescence immunoanalysis. *MedRxiv.* **2020**, 2020-04.

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.